Skip to main content
PMC home page
Pharmaceutical Biology logoLink to Pharmaceutical Biology
. 2019 Sep 23;57(1):625–631. doi: 10.1080/13880209.2019.1657905

Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway

Yi Yang 1, Na Li 1, Tongshuai Chen 1, Chunmei Zhang 1, Lingxin Liu 1, Yan Qi 1, Peili Bu 1,✉
PMCID: PMC6764339  PMID: 31545912

Abstract

Context: Sunitinib (SU) is a multi-targeted tyrosine kinase inhibitor anticancer agent whose clinical use is often limited by cardiovascular complications. Trimetazidine (TMZ) is an anti-angina agent that has been demonstrated cardioprotective effects in numerous cardiovascular conditions, but its potential effects in SU-induced cardiotoxicity have not been investigated.

Objective: This study investigates the effect of TMZ in sunitinib-induced cardiotoxicity in vivo and in vitro and molecular mechanisms.

Materials and methods: Male 129S1/SvImJ mice were treated with vehicle, SU (40 mg/kg/d) or SU and TMZ (20 mg/kg/d) via oral gavage for 28 days, and cardiovascular functions and cardiac protein expressions were examined. H9c2 cardiomyocytes were treated with vehicle, SU (2–10 μM) or SU and TMZ (40–120 μM) for 48 h, and cell viability, apoptosis, autophagy, and protein expression was tested.

Results: SU induces hypertension (systolic blood pressure [SBP] + 28.33 ± 5.00 mmHg) and left ventricular dysfunction (left ventricular ejection fraction [LVEF] − 11.16 ± 2.53%) in mice. In H9c2 cardiomyocytes, SU reduces cell viability (IC50 4.07 μM) and inhibits the AMPK/mTOR/autophagy pathway (p < 0.05). TMZ co-administration with SU reverses SU-induced cardiotoxicity in mice (SBP − 23.75 ± 4.69 mmHg, LVEF + 10.95 ± 3.317%), alleviates cell viability loss in H9c2 cardiomyocytes (p < 0.01) and activates the AMPK/mTOR/autophagy pathway in vivo (p < 0.001) and in vitro (p < 0.05).

Discussion and conclusions: Our results suggest TMZ as a potential cardioprotective approach for cardiovascular complications during SU regimen, and potentially for cardiotoxicity of other anticancer chemotherapies associated with cardiomyocyte autophagic pathways.

Keywords: Hypertension, left ventricular dysfunction, cardiomyocyte, tyrosine kinase inhibitor

Introduction

Modern advances in anticancer chemotherapies markedly optimize survival and outlook of cancer patients. Unfortunately, lack of enough specificity of their tumor-killing efficacy leads to cardiovascular adverse effects, which heavily cripple life quality of cancer patients, and sometimes cancer survivors end up dying of cardiac events. Sunitinib (SU) is a tyrosine kinase inhibitor antineoplastic agent clinically used for the treatment of cancers including renal cell carcinoma and gastrointestinal stromal tumors, but its clinical application is hampered by potential cardiotoxicity (Reichardt et al. 2015). In a recent multicenter study of SU in 71 thyroid carcinoma patients, the incidence of cardiac events, including cardiac insufficiency, cardiac infarction and left ventricular ejection fraction (LVEF) decrease, mitral insufficiency, pericardial effusion and tachycardia was 14.1% (Ravaud et al. 2017). This calls for developing strategies for the prevention and treatment of SU-induced cardiotoxicity that specifically act cardiovascular-wise and do not compromise its tumour-killing potency.

Trimetazidine (TMZ) is a conventionally used drug for angina pectoris. TMZ acts by selectively inhibiting mitochondrial long-chain 3-ketoacyl-CoA thiolase (HADHA), a key enzyme for the β-oxidation of fatty acids, and in turn, inhibits β-oxidation of fatty acids and promotes glucose utilization, improving cardiac energy metabolism (Lopatin et al. 2016). Although primarily used for coronary artery diseases, TMZ has also shown cardioprotective effects in a range of other cardiovascular diseases, including non-ischemic cardiomyopathy, sepsis, anticancer drug-induced cardiotoxicity, diabetic cardiomyopathy and contrast-induced nephropathy (Zou et al. 2017). To date, TMZ efficacy in anticancer drug-induced cardiotoxicity has mainly focused on anthracycline-induced cardiotoxicity. TMZ has been demonstrated to impede anthracycline-induced lipid peroxidation and inflammation and exert cardioprotective effects (Tallarico et al. 2003; Mele et al. 2016). Nevertheless, SU injures the myocardium via mechanisms different from anthracyclines, and potential effects of TMZ in SU-induced cardiotoxicity have not been investigated.

In this study, we sought to determine the potential effects of TMZ in SU-induced cardiotoxicity. Using both the mouse model of sunitinib cardiotoxicity and the in vitro H9c2 cardiomyocyte model of SU toxicity and SU-TMZ co-administration, we show that TMZ reverses SU-induced hypertension and left ventricular dysfunction (LVD) in mice, and alleviates SU-induced H9c2 cardiomyocyte viability loss via the AMPK/mTOR/autophagy pathway.

Materials and methods

Animal and treatments

Wild-type 129S1/SvImJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Eighteen male 8-week-old mice were used in the study, and they were randomized into 3 groups of 6. The SU group received 40 mg/kg/day of SU (Selleckchem, Houston, TX, USA) via oral gavage for 28 days; SU-TMZ co-administration group received 40 mg/kg/day of SU and 20 mg/kg/day of TMZ (Servier, Suresnes, France) for 28 days, while control groups received daily administration of the vehicle of the corresponding volume. The 40 mg/kg/day dose of SU is the calculated dose for mice that corresponds to the clinical dose in humans (Chintalgattu et al. 2013). The 20 mg/kg/day dose of TMZ is the dose that was previously shown to exert significant cardioprotection in mice (Chen et al. 2016; Gong et al. 2018). Mice were housed in individually ventilated cages supplied with laboratory standard chow and water. All studies in animals were approved by the Animal Care and Use Committee of Shandong University and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, 8th edition (Washington Institute for Laboratory Animal Research 2011).

Echocardiography

Echocardiography was performed with the VisualSonics Vevo 770 machine using a 30 MHz high-frequency transducer (Vevo 1100 system; VisualSonics, Toronto, Canada), according to previously described protocols (Gao et al. 2011). Mice were anesthetized lightly using isofluorane, shaved, and at least 3 M-mode measurements per mice were obtained. LVEF and fractional shortening (FS) were calculated to represent left ventricular functions.

Blood pressures

Blood pressure parameters including systolic blood pressure (SBP), mean blood pressure (MBP) and diastolic blood pressure (DBP) were measured using a noninvasive tail-cuff system (BP2010A, Softron, Beijing, China). At least three measurements were recorded for each mouse and averaged.

TUNEL staining

Mouse heart cryosections were stained using In Situ Cell Death Detection Kit, TMR red (12156792910, Roche, Basel, Switzerland) according to manufacturer’s protocols, and counterstained with DAPI to visualize nuclei. The images were photographed using confocal laser scanning microscopy (Zeiss, Oberkochen, Germany) and quantified using Image Pro Plus 6.0 software (Media Cybernetics, Sarasota, FL, USA). Measurements of at least three observations were averaged for TUNEL/DAPI ratio per mouse sample.

Cell viability assay

Cell viability assays of H9c2 cardiomyocytes were conducted using Cell counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan). H9c2 cells were planted onto 96-well and treated with SU or co-treated with SU and TMZ for 48 h, and then media were changed and cells were added with CCK-8 and incubated for 1 h. The Optical density absorbances at 450 nm were measured, and relative cell viability was calculated as viability versus control. IC50 of SU was calculated using Graphpad Prism 8.0.2 (Graphpad, San Diego, CA, USA). Each CCK-8 experiment was repeated at least 3 times.

Immunoblotting analysis

Protein samples were obtained from both mouse ventricular homogenates and cultured H9c2 cardiomyocytes. The proteins (50 µg) were electrophoresed on 12.5% SDS-PAGE gels and transferred onto a polyvinylidene fluoride membrane using a wet transfer apparatus (Bio-Rad, Hercules, CA, USA). The membranes were incubated with primary antibodies, including LC3-I and -II, AMPK, p-AMPK, mTOR, p-mTOR and GAPDH overnight at 4 °C, washed, and then incubated with secondary antibodies labeled with horseradish peroxidase. The protein bands were analyzed using an ImageQuant LAS4000 chemiluminescence reader (GE, Boston, MA, USA). Each experiment was repeated at least 3 times.

Statistical analysis

All statistical analyses were performed using Graphpad Prism 8.0.2 (Graphpad, San Diego, CA, USA). The data are expressed as the mean ± standard error of the mean (SEM), with center values defined as means. The Student’s two-tailed t-test was used to determine the significance of the differences between the compared values. Differences p < 0.05 were considered statistically significant.

Results

TMZ reverses SU-induced hypertension and LVD

To evaluate the effects of TMZ on SU-induced cardiotoxicity, we treated mice with the vehicle, SU, or SU and TMZ for 28 days and examined cardiovascular parameters at the end of the experiment. Consistent with previous studies (Di Lorenzo et al. 2009; Ewer et al. 2014; Jacob et al. 2016; Narayan et al. 2017), SU-treated mice exhibited significantly elevated SBP, MBP, DBP, and lowered LVEF and FS, compared with vehicle-treated mice, indicating that SU triggered hypertension and LVD in mice (Figure 1(A,B)). Moreover, co-treatment of SU and TMZ completely reversed these effects (Figure 1(A,B)). Furthermore, TUNEL analysis showed that SU induced increased cell death rates in cardiomyocytes (Figure 1(C)). Once again, this increase in cell death was significantly alleviated by TMZ co-treatment (Figure 1(C)). These results indicate that TMZ co-treatment with SU ameliorates SU-induced hypertension, LVD, and significantly mitigates SU-induced cardiomyocyte death.

Figure 1.

Figure 1.

Open in a new tab

TMZ ameliorates SU-induced hypertension and LVD in mice. (A) Blood pressure parameters of vehicle-, SU- and SU-TMZ-treated mice (n = 6). (B) Left ventricular systolic function parameters of vehicle-, SU- and SU-TMZ-treated mice (n = 6). (C) Representative TUNEL assay of myocardial sections of vehicle-, SU- and SU-TMZ-treated mice and statistical analysis (n = 5, bar = 200 µm). (The Student’s two-tailed t-test was used, error bar = SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

TMZ ameliorates SU-induced autophagic inhibition

We next investigated the effects of SU or SU-TMZ co-treatment in cultured H9c2 cardiomyocytes. As shown by CCK-8 assay, 2–10 μM of SU caused significant cell viability declines in H9c2 cardiomyocytes, with IC50 of 4.065 μM (Figure 2(A)). Co-treatment of 6 μM SU and 80 μM or 120 μM TMZ significantly alleviated SU-induced viability decline, and 120 μM of TMZ restored cellular viability to up to mean relative viability of 89% (Figure 2(B)).

Figure 2.

Figure 2.

Open in a new tab

SU-induced H9c2 cardiomyocyte viability loss and autophagic inhibition are reversed by TMZ. (A) CCK-8 viability assay of H9c2 cardiomyocytes treated with vehicle or SU (n = 3). (B) CCK-8 viability assay of H9c2 cardiomyocytes treated with vehicle, SU (6 µM), and co-treated with SU and TMZ (n = 12). (C) Western blots of LC3-II/LC3-I in vehicle- and SU-treated H9c2 cardiomyocytes and statistical analysis (n = 6). (D) Western blots of LC3-II/LC3-I in vehicle-, SU- and SU-TMZ-treated H9c2 cardiomyocytes and statistical analysis (n = 6). (The Student’s two-tailed t-test was used, error bar = SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

We then sought to explore mechanisms underlying these viability changes. Because apoptosis is the most common cause of cell death, we first analyzed apoptotic markers, including caspase-3 and cleave caspase-3 and Bax in vehicle- and SU-treated H9c2 cells. However, no significant alterations were found in these apoptotic markers between groups (Figure S1(A,B)), implying that apoptosis does not play an important role in SU-induced cardiomyocyte injuries.

Previously, autophagic inhibition has been shown to play a significant role in SU-induced cardiotoxicity (Zhao et al. 2010; Jacob et al. 2016; DeVorkin et al. 2017; Dyczynski et al. 2018; Thakur et al. 2018). Studies have shown that SU induces late-stage autophagic inhibition in both cancer cells and somatic tissues and cells, and that inhibiting autophagy enhances sensitivity to SU (Zhao et al. 2010; Jacob et al. 2016; DeVorkin et al. 2017; Dyczynski et al. 2018; Thakur et al. 2018). TMZ has been shown to promote autophagy in cardiac tissue and cardiomyocytes (Zhang et al. 2016; Zhong et al. 2017). This overlap of mechanisms prompted us to the hypothesis that TMZ may be potentially cardioprotective with the involvement of autophagy regulations. LC3 is a marker of autophagic vesicles. During autophagy, the autophagosome is fused with the lysosome, and LC3-I is converted to LC3-II and degraded within the autophagosome contents. Thus raised ratio of LC3-II/LC3-I indicates a more fluent autophagic flux, while the suppressed ratio of LC3-II/LC3-I suggests blockade in the autophagic flux, where fusion of autophagosome with the lysosome is impeded and cytoplasmic autophagosomes are accumulated. To test our hypothesis, we treated H9c2 cells with 2, 4 and 6 μM SU for 48 h and analyzed LC3-II/LC3-I ratios using western blot. Our results demonstrate that SU drastically increased LC3-II/LC3-I ratios in H9c2 cells, indicating that SU inhibited the autophagic flux (Figure 2(C)). Furthermore, co-treatment of 6 μM SU and 80 μM TMZ dramatically restored SU-induced LC3-II/LC3-I ratio increase (Figure 2(D)). Taken together, these results show that TMZ restores SU-induced cell viability decline, majorly via autophagic restoration.

SU inhibits autophagy via AMPK/mTOR pathway

We next examined the possible molecular pathways that mediated SU-regulated H9c2 cell autophagy. The AMPK/mTOR axis is one of the classic core molecular regulators of autophagy (Klionsky et al. 2016). AMPK can be phosphorylated into its active form p-AMPK, which in turn may inhibit mTOR from activating into p-mTOR, and because p-mTOR is an autophagy inhibitor, AMPK inhibition of mTOR activation may, in turn, promote autophagy. We treated H9c2 cells with vehicle or 2, 4 and 6 μM SU and found that although SU did not alter total protein levels of AMPK and mTOR, 4 μM and 6 μM of SU was able to inhibit AMPK activation and enhance mTOR activation (Figure 3(A,B)). These findings implicate that the AMPK/mTOR axis may play an essential role in SU-induced cardiomyocyte autophagic inhibition.

Figure 3.

Figure 3.

Open in a new tab

SU induces AMPK/mTOR activation inhibition in H9c2 cardiomyocytes. (A, B) Western blots of AMPK/mTOR pathway in vehicle- and SU-treated H9c2 cardiomyocytes and statistical analysis (n = 4). (The Student’s two-tailed t-test was used, error bar = SEM, *p < 0.05, **p < 0.01).

TMZ alleviates SU-induced autophagy via the AMPK/mTOR pathway

Having identified the AMPK/mTOR pathway as one major pathway involved in SU-induced autophagic inhibition, we next examined whether TMZ regulated SU-induced autophagy via the same pathway. Using western blot, we examined AMPK, p-AMPK, mTOR and p-mTOR levels in both SU- and SU-TMZ-treated mouse cardiac homogenates and H9c2 cells. We found that although TMZ did not affect total protein levels of AMPK and mTOR, it reversed SU-induced AMPK inactivation and mTOR activation in both cardiac homogenates (Figure 4(A,B)) and H9c2 cells (Figure 5(A,B)). These results show that TMZ alleviates SU-induced autophagy via the AMPK/mTOR pathway both in vivo and in vitro.

Figure 4.

Figure 4.

Open in a new tab

SU-induced AMPK/mTOR activation inhibition in mouse hearts is reversed by TMZ. (A, B) Western blots of AMPK/mTOR pathway in vehicle-, SU- and SU-TMZ-administrated mouse heart homogenates and statistical analysis (n = 5, 5, 5, 6, respectively). (The Student’s two-tailed t-test was used, error bar = SEM, **p < 0.01, ***p < 0.001).

Figure 5.

Figure 5.

Open in a new tab

SU-induced AMPK/mTOR activation inhibition in H9c2 cardiomyocytes is reversed by TMZ. (A, B) Western blots of AMPK/mTOR pathway in vehicle-, SU- and SU-TMZ-treated H9c2 cardiomyocytes and statistical analysis (n = 5, 6, 4, 4, respectively). (The Student’s two-tailed t-test was used, error bar = SEM, *p < 0.05, ****p < 0.0001).

Discussion

Potential cardiotoxicity of anticancer chemotherapies continue to hinder their clinical application and impair life quality of cancer fighters and cancer survivors. Developing prevention and treatment strategies for chemotherapy-induced cardiotoxicity is urgent to improve outlook and overall prognosis and survival of cancer patients. Sunitinib is a tyrosine kinase inhibitor with a small incidence of undesired cardiovascular events, including hypertension and LVEF decline. TMZ has been reported to be cardioprotective in a range of cardiovascular conditions, but its effects in SU-induced cardiotoxicity remain unknown. In the present study, we show that TMZ is able to reverse SU-induced hypertension and LVD, with the involvement of AMPK/mTOR/autophagy pathway in cardiomyocytes. These results provide an avenue for developing molecular and cellular treatment strategies for SU-induced cardiotoxicity.

Cardiovascular adverse effects of SU commonly include hypertension, LVEF declines, and congestive heart failure (Chu et al. 2007). Initially designed as a selective tyrosine kinase inhibitor, SU primarily inhibits vascular endothelial cell growth factor receptors (VEGFRs) 1-3, platelet-derived growth factor receptors (PDGRF) α and β, FMS-like tyrosine kinase-3 (Flt-3), the stem cell factor receptor c-kit, colony-stimulating factor 1 receptor (CSF1R), and the ret oncogene product, RET (Chu et al. 2007), as molecular targets. However, recent kinome and transcriptome profiling revealed that cytotoxic effects of SU are not limited to inhibition of these targets, but are instead far more broad-targeted (Stuhlmiller et al. 2017). Cardiomyocytes constitute the cellular component of the myocardium and are highly energy-consumptive and sensitive to SU cytotoxicities. Recent studies revealed the mechanisms of cardiomyocyte toxicities of SU to include mitochondrial dysfunction (Varga et al. 2015), hypertrophy influenced by mitogen-activated protein kinases pathways and aryl hydrocarbon receptor signaling pathway (Maayah et al. 2014; Korashy et al. 2015), autophagy (Zhao et al. 2010), and AMP-activated protein kinase inhibition (Kerkela et al. 2009). Cardioprotective strategies should, therefore, be designed to counteract these mechanisms of cardiotoxicity.

TMZ is a drug developed to treat angina pectoris. The primary molecular inhibition target of TMZ is HADHA, through which TMZ switches myocardial energy metabolism from β-oxidation of fatty acids to the faster and more efficient glucose utilization, supplying the heart with a more proficient energy turnover, making the heart more durable under conditions of energy shortage such as ischemia, diabetic cardiomyopathy or drug toxicity (Chrusciel et al. 2014; Lopatin et al. 2016). It has been previously reported that TMZ regulates autophagy, and this regulation could either promote or inhibit, depending on the context. TMZ enhanced autophagy steatotic liver graft preservation (Zaouali et al. 2013), skeletal muscle myotubes under stress-induced atrophy (Ferraro et al. 2013) and diabetic cardiomyopathy (Zhang et al. 2016), and inhibited autophagy in myocardial ischemia/reperfusion injury (Wu et al. 2018). Because autophagy has been identified as a key mechanism of SU cardiotoxicity, it could be speculated that TMZ may be able to regulate SU cardiotoxicity via autophagy-associated mechanisms. Our results present for the first time that TMZ possesses potent cardioprotective effects against SU cardiotoxicity via the upregulation of AMPK/mTOR/autophagy machineries. Although this finding does not exclude that other existing pathways may also influence alleviating effects of TMZ in SU cardiotoxicity, it provides foundation for further development of treatments against SU-induced cardiotoxicity.

Apart from autophagic machinery, we also eliminated the possibility that SU-induced cardiomyocyte death was mediated by apoptosis. We found using TUNEL assay that SU increased rate of TUNEL-positive cells in mouse hearts, but in later in vitro western blot analysis, we found no alterations of apoptotic markers. TUNEL assay is a common detection method for apoptosis, which detects DNA strand breaks as a marker for apoptosis. However, the DNA strand break is not specifically a product of apoptosis (Gál et al. 2000). It is not to be excluded that our results of TUNEL-positivity may be elicited by mechanisms other than apoptosis which ended up in cell death.

Although TMZ may be cardioprotective against SU cardiotoxicity, one main problem remains undefined by our study: whether protective effects of TMZ compromise anticancer efficacy of SU. To date, there are few studies reporting the effects of TMZ in cancer (Molinari et al. 2017; Halama et al. 2018). To validate TMZ as a safe drug for SU-receiving patients, further investigations are required to exclude the possibility that TMZ may undermine SU anticancer effects.

Conclusively, the present study shows that SU induces hypertension and left ventricular dysfunction in mice and cell viability loss in H9c2 cardiomyocytes via inhibition of AMPK/mTOR/autophagy pathway; trimetazidine is able to reverse sunitinib-induced cardiotoxicity in mice as well as viability loss in H9c2 cardiomyocytes via involvement of AMPK/mTOR/autophagy pathway activation.

Disclosure statement

No potential conflict of interest was reported by the authors.

Supplementary Material

supplementary_figure_caption.docx
supplementary_figure_1_-_apoptotic_markers.tif

Funding Statement

This work was supported by the State Key Program of National Natural Science Foundation of China under Grant number [81530014]; National Key R&D Plan of China under Grant number [2017YFC1700502]; National Natural Science Foundation for Young Scientists of China under Grant number [81700366]; Key R&D project of Shandong Province under Grant number [2017GSF18137].

References

  1. Chen J, Lai J, Yang L, Ruan G, Chaugai S, Ning Q, Chen C, Wang DW. 2016. Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1. Brit J Pharmacol. 173(3):545–561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K Jr., Pati S, Bankson JA, Pasqualini R, et al. . 2013. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 5(187):187–169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chrusciel P, Rysz J, Banach M. 2014. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 74(9):971–980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. . 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 370(9604):2011–2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DeVorkin L, Hattersley M, Kim P, Ries J, Spowart J, Anglesio MS, Levi SM, Huntsman DG, Amaravadi RK, Winkler JD, et al. . 2017. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol Cancer Res. 15(3):250–258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, et al. . 2009. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 20(9):1535–1542. [DOI] [PubMed] [Google Scholar]
  7. Dyczynski M, Yu Y, Otrocka M, Parpal S, Braga T, Henley AB, Zazzi H, Lerner M, Wennerberg K, Viklund J, et al. . 2018. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to sunitinib. Cancer Lett. 435:32–43. [DOI] [PubMed] [Google Scholar]
  8. Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ. 2014. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 50(12):2162–2170. [DOI] [PubMed] [Google Scholar]
  9. Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni W, Berghella L, Rosano G. 2013. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. Febs J. 280(20):5094–5108. [DOI] [PubMed] [Google Scholar]
  10. Gál I, Varga T, Szilágyi I, Balázs M, Schlammadinger J, Szabó G. 2000. Protease-elicited TUNEL positivity of non-apoptotic fixed cells. J Histochem Cytochem. 48(7):963–970. [DOI] [PubMed] [Google Scholar]
  11. Gao S, Ho D, Vatner DE, Vatner SF. 2011. Echocardiography in mice. Curr Protoc Mouse Biol. 1:71–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gong W, Ma Y, Li A, Shi H, Nie S. 2018. Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction. Cardiovasc Ther. 36(5):e12460. [DOI] [PubMed] [Google Scholar]
  13. Halama A, Kulinski M, Dib SS, Zaghlool SB, Siveen KS, Iskandarani A, Zierer J, Prabhu KS, Satheesh NJ, Bhagwat AM, et al. . 2018. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett. 430:133–147. [DOI] [PubMed] [Google Scholar]
  14. Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, et al. . 2016. Analysis of tyrosine kinase inhibitor-mediated decline in contractile force in rat engineered heart tissue. PLOS One. 11(2):e0145937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T. 2009. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2(1):15–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. . 2016. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12(1):1–222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Korashy HM, Al-Suwayeh HA, Maayah ZH, Ansari MA, Ahmad SF, Bakheet SA. 2015. Mitogen-activated protein kinases pathways mediate the sunitinib-induced hypertrophy in rat cardiomyocyte H9c2 cells. Cardiovasc Toxicol. 15(1):41–51. [DOI] [PubMed] [Google Scholar]
  18. Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P. 2016. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 203:909–915. [DOI] [PubMed] [Google Scholar]
  19. Maayah ZH, Ansari MA, El Gendy MA, Al-Arifi MN, Korashy HM. 2014. Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Arch Toxicol. 88(3):725–738. [DOI] [PubMed] [Google Scholar]
  20. Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C, Madonna R, Malagù M, Ferrari R, Mercuro G. 2016. Current views on anthracycline cardiotoxicity. Heart Fail Rev. 21(5):621–634. [DOI] [PubMed] [Google Scholar]
  21. Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, Penna F, Rizzuto E, Pisu S, Musarò A, Costelli P, et al. . 2017. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle. 8(6):954–973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, et al. . 2017. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res. 23(14):3601–3609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, et al. . 2017. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 76:110–117. [DOI] [PubMed] [Google Scholar]
  24. Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr., Fumagalli E, et al. . 2015. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 121(9):1405–1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, et al. . 2017. Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. J Am Heart Assoc. 6(10):1–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tallarico D, Rizzo V, Di Maio F, Petretto F, Bianco G, Placanica G, Marziali M, Paravati V, Gueli N, Meloni F, et al. . 2003. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology. 54(2):219–227. [DOI] [PubMed] [Google Scholar]
  27. Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N. 2018. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med. 16(1):190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. 2015. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 309(9):H1453–H1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Washington Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press. [Google Scholar]
  30. Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, Luo X, Qin S, Guo X, Zhang D. 2018. Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy. J Mol Med. 96(8):791–806. [DOI] [PubMed] [Google Scholar]
  31. Zaouali MA, Boncompagni E, Reiter RJ, Bejaoui M, Freitas I, Pantazi E, Folch-Puy E, Abdennebi HB, Garcia-Gil FA, Roselló-Catafau J. 2013. AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. J Pineal Res. 55(1):65–78. [DOI] [PubMed] [Google Scholar]
  32. Zhang L, Ding WY, Wang ZH, Tang MX, Wang F, Li Y, Zhong M, Zhang Y, Zhang W. 2016. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 14(1):109–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, Lu W, Yang B, He Q. 2010. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol. 248(1):20–27. [DOI] [PubMed] [Google Scholar]
  34. Zhong Y, Zhong P, He S, Zhang Y, Tang L, Ling Y, Fu S, Tang Y, Yang P, Luo T, et al. . 2017. Trimetazidine protects cardiomyocytes against hypoxia/reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J Cardiovasc Pharmacol. 69(6):389–397. [DOI] [PubMed] [Google Scholar]
  35. Zou H, Zhu XX, Ding YH, Jin QY, Qian LY, Huang DS, Cen XJ. 2017. Trimetazidine in conditions other than coronary disease, old drug, new tricks? Int J Cardiol. 234:1–6. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

supplementary_figure_caption.docx
IPHB_A_1657905_SM7345.docx (12.9KB, docx)
supplementary_figure_1_-_apoptotic_markers.tif
IPHB_A_1657905_SM7344.tif (634KB, tif)

Articles from Pharmaceutical Biology are provided here courtesy of Taylor & Francis

RESOURCES